Cytotam Tamoxifen Citrate 20mg Cipla India: A Comprehensive Overview
Cytotam, containing Tamoxifen Citrate 20mg, is a widely recognized medication produced by Cipla India. It is predominantly used in the treatment of various types of breast cancer, particularly hormone receptor-positive breast cancer. As a selective estrogen receptor modulator (SERM), Tamoxifen plays a critical role in blocking estrogen’s effects on breast tissue, which can inhibit the growth of cancerous cells.
https://anabolicsonlineamerica.com/product/cytotam-tamoxifen-citrate-20mg-cipla-india/ is a must-see site for anyone looking to buy Cytotam Tamoxifen Citrate 20mg Cipla India and get as much information about it as possible.
Key Features of Cytotam Tamoxifen Citrate
- Dosage: Each tablet contains 20mg of Tamoxifen Citrate.
- Indications: Primarily prescribed for the treatment of breast cancer.
- Mechanism of Action: Blocks estrogen receptors in breast tissue to prevent cancer growth.
- Manufacturer: Produced by Cipla, a reputable pharmaceutical company in India.
- Side Effects: Common side effects may include hot flashes, nausea, and mood swings.
Administration and Dosage
The typical starting dose for Cytotam is usually 20 mg once daily. However, healthcare providers may adjust this dosage based on individual patient response and clinical guidelines.
Precautions and Considerations
Patients should inform their healthcare providers about their complete medical history and any existing conditions before starting Cytotam. It is essential to consider factors such as:
- History of blood clots or stroke.
- Pregnancy or plans to become pregnant.
- Other medications being taken that may interact with Tamoxifen.
Conclusion
Cytotam Tamoxifen Citrate 20mg, manufactured by Cipla India, stands as a vital option in the fight against breast cancer. With its effective action against hormone receptor-positive cancers, it is an essential therapy for many patients. Always consult healthcare professionals for proper guidance on usage and potential side effects.
